Overview

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Status:
Completed

Trial end date:
2021-02-10

Target enrollment:

Participant gender:

Summary

This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab